title: Primary lymphoma of the central nervous system. An unresolved therapeutic problem.
abstract: From January 1979 to December 1987, 35 cases of primary central nervous system lymphoma (CNS-L) were treated. We recently reviewed these cases focusing on treatment results, treatment modalities, and radiotherapy (RT) or chemotherapy-radiotherapy (CT-RT). Variables such as age, risk factors, presenting symptoms, and histologic condition (all were high-grade or intermediate-grade non-Hodgkin's lymphomas [NHL]) and radiologic data were similar to those of series reported previously. The median survival time was 36 months (+/- 0.2 months) and the disease-free survival (DFS) time was 16 months (+/- 0.12 months). Twelve of 32 patients evaluable for treatment results experienced a recurrence (all but one occurred in the CNS). The DFS rate was 70% for the CT-RT group and 50% for the RT group (median follow-up time, 24 months). Therapeutic results in CNS-L are discussed with special emphasis on a putative role of CT in the management of this rare type of tumor.
authors.affiliation: Centre des Tumeurs, Hôpital Tenon, Paris, France.
authors.forename: G
authors.initials: G
authors.lastname: Socié
authors.forename: C
authors.initials: C
authors.lastname: Piprot-Chauffat
authors.forename: M
authors.initials: M
authors.lastname: Schlienger
authors.forename: D
authors.initials: D
authors.lastname: Legars
authors.forename: C
authors.initials: C
authors.lastname: Thurel
authors.forename: J
authors.initials: J
authors.lastname: Mikol
authors.forename: N
authors.initials: N
authors.lastname: Ifran
authors.forename: J
authors.initials: J
authors.lastname: Brière
authors.forename: F
authors.initials: F
authors.lastname: Pene
authors.forename: B
authors.initials: B
authors.lastname: Gindrey-Vie
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000401:mortality / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D012307:Risk Factors; D016019:Survival Analysis